ArticleJournal of advanced veterinary and animal research2025
The extract of zedoary-turmeric protects rats' kidneys from damage caused by cisplatin.
Article in Journal of advanced veterinary and animal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The goal of this study was to examine how the combination of Materials and Methods: There were five groups of rats: a normal control group, a cisplatin control group (CP), and three extract treatment groups (Ext100, Ext200, and Ext400). The CP group got cisplatin on day seven to cause AKI, while the extract group got cisplatin on day seven and the combined extract on days one through nine. On the 10th day, we looked at body weight, kidney weight, histology, and gene expression of Results: Body weight decreased in the CP group, while it initially decreased and then increased in the extract groups, with Ext200 showing the greatest increase. Histologically, the CP group exhibited severe kidney damage, whereas the Ext200 group showed reduced damage. Gene expression of Conclusion: Cisplatin-induced AKI caused less damage to the kidneys and less production of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.